Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.61 |
| ▸ | DRD2 | P14416 | 5/20 | 0.61 |
| ▸ | DRD4 | P21917 | 5/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739424 | 0.89 | ALDH1A1 (0.56) | MCHR1DRD2DRD4SIGMAR1POLB | |
| SCHEMBL2925228 | 0.88 | SIGMAR1 (0.66) | MCHR1DRD4SIGMAR1 | |
| SCHEMBL2925226 | 0.88 | SIGMAR1 (0.66) | MCHR1DRD4SIGMAR1 | |
| SCHEMBL30408347 | 0.86 | ALDH1A1 (0.56) | MCHR1DRD2SIGMAR1 | |
| SCHEMBL239527 | 0.85 | DRD4 (0.71) | MCHR1DRD2DRD4SIGMAR1 | |
| SCHEMBL239528 | 0.85 | DRD4 (0.71) | MCHR1DRD2DRD4SIGMAR1 | |
| SCHEMBL5692127 | 0.85 | CTSL (0.67) | MCHR1DRD2DRD4SIGMAR1 | |
| SCHEMBL17961749 | 0.84 | DRD4 (0.70) | MCHR1DRD2DRD4SIGMAR1POLB | |
| SCHEMBL20183285 | 0.84 | DRD4 (0.70) | MCHR1DRD2DRD4SIGMAR1POLB | |
| SCHEMBL19614234 | 0.84 | DRD4 (0.70) | MCHR1DRD2DRD4SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | MCHR1 1979/4885DRD2 686/4885DRD4 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.